Efficacy and Safety of Empagliflozin (BI 10773) With Metformin in Patients With Type 2 Diabetes

Inclusion criteria: * Diagnosis typ 2 diabetes mellitus * Male and female on diet and exercise regimen, pre-treated with metformin 12 weeks prior to randomisation * HbA1c equal or greater than 7.0% and less than or equal to 10% at visit 1 * 18 years or more * BMI equal or less than 45Kg/m2 Exclusion criteria: * Uncontrolled hyperglycemia defined as glucose more that 13.3 mmol/L after overnight fast during placebo run-in * Any other antidiabetic drug within 12 weeks prior to randomisation except metformin * Acute coronary syndrome (non-STEMI, STEMI unstable angina pectoris), stroke or transient ischemic attack within 12 weeks of informed consent * Indication of liver disease * Moderate to severe renal impairment * Bariatric surgery within past 2 years * Medical history of cancer or treatment for cancer within last 5 years * Blood dyscrasias or any disorders causing haemolysis or unstable red blood cell * Contraindications hypersensitivity to concomitant drugs * Treatment with anti-obesity drugs